Elobixibat
As of the edition of 20 October 2026, Elobixibat is a small molecule: marketed, first approved in 2018 (JP); acts on SLC10A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Goofice
- First approved
- 19 January 2018 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- EA Pharma
- Registered trials
- 12, 4 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Elobixibat.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC10A2 | Ileal sodium/bile acid cotransporter | Q12908 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 3 | 1 | 0 | 2 |
| Phase 4 | 3 | 0 | 0 | 1 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| EA Pharma | Applicant | 2018 to now |